S'identifier

The orderly progression of the cell cycle depends on the activation of CDK protein by binding to its cyclin partner. However, the cell cycle must be restricted when the cell undergoes abnormal changes. Most cancers correlate to the deregulated cell cycle, and since CDKs are a central component of the cell cycle, the CDK inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several CDKs, such as CDK 4/6, to form an active complex. The cyclin D-CDK4/6 complex then phosphorylates and inactivates the tumor suppressor retinoblastoma protein (Rb) to promote the G1-to-S phase transition of the cell cycle. In normal cells, Rb protein is reactivated through the regulation of CDK activity, thus, preventing abnormal cell cycle transitions.

There are at least three known mechanisms by which CDK activity is regulated- cyclin degradation, inhibitory phosphorylation, or binding of inhibitory proteins. Mutations that prevent these mechanisms lead to CDK-mediated tumorigenesis.

Because CDK 4/6 plays a substantial role in tumor formation, several CDK inhibitors have been developed for clinical use. The most recent ones are selective for CDK4 and CDK6. There are at least three clinically approved CDK 4/6 inhibitors: abemaciclib, ribociclib, and palbociclib. These inhibitors bind to the ATP pocket of CDK 4 and 6, inactivating the Cyclin D-CDK4/6 complexes, leading to Rb protein activation and subsequent cell cycle arrest. In some cases, the inhibitor-mediated cell cycle arrest causes an increase in apoptosis in tumor cells.

Inhibition of the cell cycle and subsequent programmed cell death are the most common mechanisms of CDK4/6 inhibitors. However, a recent study in mouse models of breast cancer showed that CDK4/6 inhibition could also lead to severe immunogenic effects. During the study, the CDK inhibitor seemed to enhance tumor cells' antigen-presenting ability, thereby allowing cytotoxic T cells to recognize and destroy the tumor cells.

Tags
CDK ActivityCDK InhibitionCell Cycle RegulationCyclin dependent KinaseCell DivisionCancer TherapySignal Transduction

Du chapitre 34:

article

Now Playing

34.5 : Inhibition of CDK Activity

Cell Proliferation

4.5K Vues

article

34.1 : Qu’est-ce que le cycle cellulaire ?

Cell Proliferation

6.2K Vues

article

34.2 : Interphase

Cell Proliferation

5.8K Vues

article

34.3 : Le système de contrôle du cycle cellulaire

Cell Proliferation

6.0K Vues

article

34.4 : Molécules régulatrices positives

Cell Proliferation

4.2K Vues

article

34.6 : Le S-CDK initie la réplication de l’ADN

Cell Proliferation

2.0K Vues

article

34.7 : M-CDK favorise la transition vers la mitose

Cell Proliferation

1.9K Vues

article

34.8 : Les mitogènes et le cycle cellulaire

Cell Proliferation

3.9K Vues

article

34.9 : Sénescence cellulaire réplicative

Cell Proliferation

2.4K Vues

article

34.10 : Prolifération anormale

Cell Proliferation

2.0K Vues

article

34.11 : Les cellules coordonnent la croissance et la prolifération

Cell Proliferation

2.3K Vues

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.